natgillin/translations-raw huggingface dataset:
That cardiac disorders (including arrhythmias) may arise in newborn infants with pre- existing cardiac disease
Podatek, da se lahko pri novorojenčkih z že obstoječimi srčnimi boleznimi pojavijo srčne motnje (vključno z aritmijami).
That children may be at increased risk of developing infections and that their immunisations need to be up to date.
da se lahko pri otrocih poveča tveganje za okužbe in je zato pri njih treba redno opravljati vsa cepljenja, v skladu s programom.
That children may be at increased risk of developing infections and that their immunisations need to be up-to-date.
da se lahko pri otrocih poveča tveganje za okužbe in je zato pri njih treba redno opravljati vsa cepljenja, v skladu s programom.
That children may be at increased risk of developing infections and that their immunisations need to be up-to-date.
Da so otroci lahko izpostavljeni povečanemu tveganju za razvoj okužb in da morajo biti redno imunizirani, skladno z načrtom za njihovo starost.
That chronic administration of Volibris in animals has been linked to testicular tubular atrophy and impaired fertility.
Da je bila dolgotrajna uporaba zdravila Volibris pri živalih povezana z atrofijo testikularnih tubulov in motnjami plodnosti.
that co-administration is not recommended with tenofovir, boceprevir, carbamazepine, phenytoin, phenobarbital, proton pump inhibitors, and buprenorphine. that co-administration with famotidine is not recommended but if required, atazanavir without ritonavir should be administered either 2 hours after famotidine or 12 hours before.
očasna uporaba ni priporočljiva s tenofovirjem, boceprevirjem, karbamazepinom, fenitoinom, fenobarbitalom, zaviralci protonske črpalke in buprenorfinom. sočasna uporaba s famotidinom ni priporočljiva, če pa je potrebna, mora bolnik atazanavir brez ritonavirja vzeti 2 uri po famotidinu ali 12 ur pred famotidinom.
That cobicistat inhibits the tubular secretion of creatinine and may cause modest increases in serum creatinine and modest declines in creatinine clearance without affecting renal glomerular function.
da kobicistat zavira tubularno sekrecijo kreatinina in lahko povzroči zmerno zvišanje serumskega kreatinina in zmerno znižanje očistka kreatinina, kar pa ne vpliva na ledvično glomerularno funkcijo.
That deferasirox causes rises in serum creatinine in some patients
dejstvo, da deferasiroks pri nekaterih bolnikih povzroča zvišanje koncentracije kreatinina v serumu
That dose adjustment is needed when patients are switched from one to the other strength:
Da je v primeru prehoda bolnika z ene jakosti na drugo treba prilagoditi odmerek:
That during treatment with Ranexa the patient should:
Med zdravljenjem z zdravilom Ranexa bolnik:
That Eurartesim has a potential to prolong the QTc interval that may lead to potentially lethal arrhythmias.
Zdravilo Eurartesim lahko podaljša interval QTc, kar lahko povzroči aritmije, ki so lahko usodne.
That Eurartesim is contraindicated in patients with severe malaria according to WHO definition and in patients with a history of clinical conditions that may lead to QTc interval prolongation, and in patients taking drugs that are known to prolong the QTc interval.
Zdravilo Eurartesim je kontraindicirano pri osebah s hudo obliko malarije po opredelitvi SZO in pri bolnikih z anamnezo kroničnih stanj, ki lahko povzročijo podaljšanje intervala QTc, ter pri bolnikih, ki jemljejo zdravila, za katera je znano, da podaljšajo interval QTc.
That for the multi-dose nasal spray and multi-dose nasal spray DoseGuard all unused devices or empty containers should be returned systematically according to the local regulation.
Da je pri večodmernem pršilu za nos in večodmernem pršilu za nos DoseGuard treba vsa neuporabljena pršila ali prazne vsebnike sistematično vračati v skladu z lokalnimi predpisi.
That for the single-dose nasal spray all unused devices or empty containers should be returned systematically according to the local regulation.
Da je pri enoodmernem pršilu za nos treba vsa neuporabljena pršila ali prazne vsebnike sistematično vračati v skladu z lokalnimi predpisi.
That GILENYA is teratogenic so women with childbearing potential must:
Zdravilo GILENYA je teratogeno, zato morajo ženske v rodni dobi:
That he should not donate blood or semen during therapy and for one week following discontinuation of thalidomide
med zdravljenjem in še en teden po ukinitvi jemanja talidomida ne sme darovati krvi ali sperme
That he should not donate semen or sperm during therapy (including during dose interruptions) and for 7 days after discontinuation of pomalidomide treatment
da ne sme darovati semena ali sperme med zdravljenjem (tudi med prekinitvami odmerjanja ne) in še 7 dni po končanju zdravljenja s pomalidomidom;
That hormonal contraceptives on their own are not effective
da samo hormonska kontracepcija ni učinkovita
That hypersensitivity reactions (e.g. angioedema, rash), although uncommon in short term clinical trials and common in longer term trials and in combination with tadalafil, have been reported with Volibris.
Da so med uporabo zdravila Volibris občasno poročali o preobčutljivostnih reakcijah (kot so angioedem, izpuščaj) v kratkoročnih kliničnih preskušanjih in pogosto v daljših preskušanjih ter v kombinaciji s tadalafilom.
That if a woman of child-bearing potential needs to change or stop her method of contraception she should inform the physician prescribing her contraception that she is taking Volibris.
Ženska v rodni dobi, ki mora spremeniti ali prenehati uporabljati dosedanjo kontracepcijo, mora zdravnika, ki ji je predpisal kontracepcijo, obvestiti, da jemlje zdravilo Volibris.
That if a women of child-bearing potential needs to change or stop her method of contraception she should inform the physician prescribing Volibris.
Ženska v rodni dobi, ki mora spremeniti ali prenehati uporabljati dosedanjo kontracepcijo, mora o tem obvestiti zdravnika, ki ji je predpisal zdravilo Volibris.
That if caffeine and doxapram are used concurrently, the patient should be closely monitored
Podatek, da je treba bolnika pri sočasni uporabi kofeina in doksaprama natančno spremljati.
That if his partner becomes pregnant he should inform his treating doctor immediately and always use a condom
če partnerica zanosi, mora o tem takoj obvestiti zdravnika, ki ga zdravi, in vedno uporabljati kontom
That if his partner becomes pregnant whilst he is taking pomalidomide or shortly after he has stopped taking pomalidomide he should inform his treating doctor immediately
da mora v primeru, če partnerica zanosi, medtem ko bolnik jemlje pomalidomid ali kmalu po prenehanju jemanja pomalidomida, takoj obvestiti svojega lečečega zdravnika.
That if she needs to change or stop using her method of contraception she should inform:
opozorilo, da mora v primeru spremembe ali prenehanja uporabe svoje kontracepcijske metode obvestiti:
That if she needs to change or stop using her method of contraception she should inform:
opozorilo, da mora ženska, če želi spremeniti ali zamenjati svojo kontracepcijsko metodo, obvestiti
That if she needs to change or stop using her method of contraception she should inform:
če želi ženska spremeniti ali zamenjati svojo kontracepcijsko metodo, mora obvestiti
That increased exposure might occur in certain populations and increase the risk of persistent intolerability:
Pri določenih populacijah lahko pride do povečane izpostavljenosti in povečanega tveganja za trajno intoleranco:
That INCRELEX should be administered shortly before or after a meal or snack because it has insulin-like hypoglycaemic effects.
Zdravilo INCRELEX je treba dati neposredno pred ali po obroku oziroma prigrizku, saj ima insulinu podobne hipoglikemične učinke.
That insulin glargine 100 units/ml and insulin glargine 300 units/ml (Toujeo 300 units/ml) are not bioequivalent and are therefore not interchangeable without dose adjustment.
Da insulin glargin 100 enot/ml in insulin glargin 300 enot/ml (zdravilo Toujeo 300 enot/ml) nista bioekvivalentna in zato nista medsebojno zamenljiva brez prilagoditve odmerka.
That it is the responsibility of the prescribing physician to determine which patients may be suitable for home or self-administration of Fabrazyme.
Da je odgovornost zdravnika, ki predpiše zdravilo Fabrazyme, da presodi, kateri bolniki so primerni za dajanje zdravila na domu ali za samo dajanje.
That it is the responsibility of the prescribing physician to provide appropriate training to the non-healthcare professional, such as the patient for self-administration or a caregiver who will administer the treatment at home, if the treating physician decides that this is appropriate.
Da je zdravnik, ki predpiše zdravilo Fabrazyme, odgovoren za ustrezno usposabljanje nezdravstvenega osebja, kot je bolnik v primeru samodajanja ali negovalec v primeru uporabe zdravila na domu, če lečeči zdravnik presodi, da je to primerno.
That Lojuxta was teratogenic in non-clinical studies and that women of child-bearing potential must be non-pregnant and using effective contraception prior to initiating treatment.
V predkliničnih študijah je bilo zdravilo Lojuxta teratogeno, zato ženske v rodni dobi ne smejo zanositi in morajo pred uvedbo zdravljenja uporabljati učinkovito kontracepcijo.
That Lomitapide was teratogenic in non-clinical studies and is contraindicated in women who are or may become pregnant.
Da je bil lomitapid v predkliničnih študijah teratogen, zato je kontraindiciran pri nosečnicah ali ženskah, ki lahko zanosijo.
That MACI is an autologous product and should only be administered to the patient that the biopsy was taken from.
Da je zdravilo MACI avtologni izdelek in da se uporablja le pri bolnikih, ki so jim z biopsijo odvzeli hrustanec.
That means it is essentially ‘sodium-free’.
To pomeni, da je skoraj »brez natrija«.
That Nivolumab BMS treatment may increase the risk of:
Pri zdravljenju z zdravilom Nivolumab BMS se lahko poveča tveganje za:
that no more than two injections of hydroxocobalamin are to be administered,
uporabljeni ne bosta več kot dve injekciji hidroksokobalamina,
That of the active metabolite is decreased by 47% (see section 4.2).
Izpostavljenost aktivnemu presnovku se poveča za 47 % (glejte poglavje 4.2).
That OPDIVO treatment may increase the risk of:
Pri zdravljenju z zdravilom OPDIVO se lahko poveča tveganje za:
That patients should be advised to contact their doctor about adverse events and that physicians/pharmacists should report suspected adverse reactions to Eurartesim, and in particular, those associated with a QT prolongation.
Bolnike je treba opozoriti, da se o neželenih učinkih posvetujejo z zdravnikom, in da mora zdravnik/farmacevt poročati sum na neželene učinke z zdravilom Eurartesim, še zlasti tiste, povezane s podaljšanjem intervala QT.
That patients should be capable of complying with the requirements for the safe use of pomalidomide
bolniki morajo biti sposobni upoštevati zahteve za varno uporabo pomalidomida,
That patients should be capable of complying with the requirements for the safe use of thalidomide
bolniki morajo biti sposobni izpolnjevati zahteve za varno rabo talidomida,
That patients should be capable of complying with the requirements for the safe use of Volibris.
presoditi morajo, da so bolniki sposobni izpolnjevati zahteve glede varne uporabe zdravila Volibris;
That patients should be counselled that:
Bolnikom je treba povedati, da:
That patients should have examinations of the ears, nose and throat periodically and at the occurrence of clinical symptoms to rule out such potential complications or to initiate appropriate treatment.
Bolniki morajo imeti redne preglede ušes, nosu in grla in pri pojavu kliničnih simptomov je treba preprečiti tovrstne morebitne zaplete ali začeti z ustreznim zdravljenjem.
That patients should have their baseline renal function assessed prior to initiating Atripla therapy
Da je treba pred uvedbo zdravljenja z zdravilom Atripla oceniti bolnikovo izhodiščno delovanje ledvic
that patients should not be taking anti-platelet or other anti-coagulation medicinal products at the time of injection
opozorilom, da bolniki v času injiciranja ne smejo jemati antiagregacijskih ali antikoagulacijskih zdravil;
That patients treated with Ruconest should be monitored for clinical signs and symptoms of hypersensitivity during administration.
da je treba bolnike, zdravljene z zdravilom Ruconest, med dajanjem spremljati glede preobčutljivostnih kliničnih znakov in simptomov.
That patients treated with Ruconest should be monitored for clinical signs and symptoms of hypersensitivity during administration.
informacijo, da je treba bolnike, zdravljene z zdravilom Ruconest, med dajanjem zdravila spremljati glede kliničnih znakov in simptomov preobčutljivosti.
That patients’ renal function should be assessed and monitored and initial dose and dosage adjustments should be calculated based on the creatinine clearance.
Oceniti in spremljati je treba delovanje ledvic, začetni odmerek in prilagoditve odmerka pa je treba izračunati na podlagi očistka kreatinina.
That Peyona is for the treatment of primary apnoea
Zdravilo Peyona je namenjeno zdravljenju primarne apneje.
That PhotoBarr
Zdravilo PhotoBarr
That piperaquine absorption is increased in the presence of food, therefore to reduce this risk of QTc interval prolongation, the patients should be advised to take the tablets with water, without food, no less than three hours after the last food intake.
Absorpcija piperakina se poveča v prisotnosti hrane, zato je treba bolnikom svetovati, da zmanjšajo tveganje podaljšanja intervala QTc tako, da zdravilo vzamejo z vodo in brez hrane vsaj tri ure po zadnjem zaužitju hrane.
That pomalidomide is teratogenic in animals and is expected to be teratogenic in humans
opozorilo, da je pomalidomid teratogen pri živalih in se pričakuje teratogenost pri človeku;
That pomalidomide may cause neutropenia and thrombocytopenia and the need for regular blood tests
da pomalidomid lahko povzroča nevtropenijo in trombocitopenijo; potrebne so redne krvne preiskave;
That prior to Ranexa treatment the patient should tell their doctor if they have any of the following:
Pred zdravljenjem z zdravilom Ranexa mora bolnik obvestiti zdravnika, če:
That Ruconest is derived from milk of transgenic rabbits and contains trace of rabbit proteins
da je zdravilo Ruconest pridobljeno iz mleka transgenskih kuncev in vsebuje sledove kunčjih beljakovin;
That she should not share the treatment with any other person
vojega zdravila ne sme dajati nikomur drugemu
That thalidomide is found in semen and the need to use condoms if sexual partner is pregnant or is a women with childbearing potential not on effective contraception
opozorilo, da je talidomid prisoten v spermi in o potrebi zaščite s kondomom, če je spolna partnerica noseča ali v rodni dobi in ne uporablja zanesljive kontracepcije
That thalidomide is found in semen and the need to use condoms if sexual partner is pregnant or is a women with childbearing potential not on effective contraception
talidomid je prisoten v spermi, zato mora pri spolni partnerici, ki je noseča ali v rodni dobi in ne uporablja zanesljive kontracepcije, uporabiti kondom
That thalidomide is found in semen and the need to use condoms if sexual partner is pregnant or is a women with childbearing potential not using effective contraception
opozorilo, da je talidomid prisoten v spermi in o potrebi zaščite s kondomom, če je spolna partnerica noseča ali v rodni dobi in ne uporablja zanesljive kontracepcije
That the benefit risk balance for the Complicated Skin and Soft Tissue Infections indication was assessed as negative by the Committee for Medicinal Products for Human Use (CHMP), therefore Vibativ should not be used in this or other indications not approved.
Odbor za zdravila za uporabo v humani medicini (CHMP) je ocenil razmerje med koristmi in tveganji za indikacijo zapletenih okužb kože in mehkega tkiva kot negativno, zato se zdravilo Vibativ ne sme uporabljati za to in za druge neodobrene indikacije.
That the card should be shown to any doctor involved in their treatment
Bolnik mora kartico pokazati vsakemu zdravniku, ki sodeluje v njegovem zdravljenju.
That the dose is once daily
Odmerek se vzame enkrat na dan.
That the dose newly recommended by their healthcare provider should always be followed;
Da je vedno treba uporabljati odmerek, ki ga je na novo naročil zdravnik.
That the dose of caffeine expressed as caffeine base is one half the dose of caffeine expressed as caffeine citrate (20mg caffeine citrate is equivalent to 10mg caffeine base) and that prescriptions should clearly indicate that caffeine citrate is to be administered.
Podatek, da je odmerek kofeina, izražen kot kofein, ena polovica odmerka kofeina, izraženega kot kofeinijev citrat (20 mg kofeinijevega citrata je enakovredno 10 mg kofeina) in da morajo recepti jasno navajati, da je treba uporabiti kofeinijev citrat.
That the latter two half-lives, and especially that for oral administration, are longer than for i.v. administration probably reflects the complex absorption and distribution of glycopyrronium by each route.
Ti razpolovni dobi, zlasti doba za peroralno uporabo, sta daljši kot razpolovna doba za intravensko uporabo, kar verjetno odraža zapleteno absorpcijo in porazdelitev glikopironija po vsaki poti.
That the medicinal product should be used immediately after opening the ampoule and unused portions left in the ampoule should be discarded
Podatek, da je treba zdravilo uporabiti takoj po odprtju ampule, neuporabljen delež v ampuli pa je treba zavreči.
That the patient should not breastfeed during treatment and for 20 months after their final dose
opozorilo, da bolnice ne smejo dojiti v času zdravljenja in še najmanj 20 mesecev po prejemu zadnjega odmerka
That the patient should not breastfeed during treatment and for 24 months after their final dose
Da bolnice ne smejo dojiti med zdravljenjem in 24 mesecev po končanem zdravljenju
That the patient should not donate blood
da bolniki ne smejo darovati krvi
That the patient should not donate blood
opozorilo, da bolnik ne sme darovati krvi;
That the patient should not donate blood during treatment and for 24 months after their final dose
Da bolniki ne smejo darovati krvi med zdravljenjem in 24 mesecev po končanem zdravljenju
That the patient should not give pomalidomide to any other person
opozorilo, da bolnik ne sme dajati pomalidomida nobeni drugi osebi;
That the patient should tell the healthcare professional about any adverse event
Da mora bolnik obvestiti zdravstvene delavce o katerem koli neželenem učinku
That the patient should tell the healthcare professional about any adverse event
navodilo, da mora bolnik obvestiti zdravstvene delavce o kakršnemkoli neželenem dogodku
that the product should only be used once details of the post marketing surveillance studies including information on how to enroll patients
podrobne informacije o študijah nadzora v obdobju trženja, vključno z informacijami o tem, kako so se vključevali bolniki.
That the risk of infusion reactions is highest in first week of therapy
da je tveganje reakcij po infundiranju najvišje v prvem tednu zdravljenja
That the risk of PML increases with increasing duration of treatment and that treatment beyond 24 months carries additional risk and other factors associated with an increased risk for the development of PML
Da tveganje PML narašča s trajanjem zdravljenja in da zdravljenje, ki traja dlje kot 24 mesecev, predstavlja še dodatno tveganje in drugi dejavniki, povezani s povečanim tveganjem za razvoj PML
That the safety database of Thelin is limited and physicians are encouraged to enrol patients in a surveillance programme to increase knowledge about the incidence of important adverse drug reactions (ADRs).
da je baza podatkov o varnosti zdravila Thelin omejena, zato so zdravniki vabljeni, da bolnike vključijo v program nadzorovanja in s tem poglobijo znanje o incidenci pomembnih neželenih učinkov zdravila (ADRs).
That the switch from one insulin therapy to another should only be done when prescribed by their healthcare provider;
Da je prehod z enega insulinskega zdravljenja na drugega treba opraviti le, če ga je predpisal zdravnik.
That their heart rate will need to be monitored for 6 or more hours after the first dose of GILENYA, including hourly pulse and blood pressure checks.
Bolnikovo srčno frekvenco bo treba spremljati 6 ur ali več po prvem odmerjanju zdravila GILENYA, kar vključuje merjenje frekvence pulza in krvnega tlaka vsako uro.
That Thelin is hepatotoxic
da je zdravilo Thelin hepatotoksično
That Thelin is teratogenic
da je zdravilo Thelin teratogeno
That there is a potential risk of teratogenicity and so Eurartesim should not be used in situations where other suitable and effective anti-malarials are available.
Zaradi možne teratogenosti se zdravila Eurartesim ne sme uporabljati, če so na voljo drugi primerni in učinkoviti antimalariki.
That there is a potential risk of teratogenicity and Vibativ is contraindicated during pregnancy.
Obstaja možno tveganje za teratogenost, zato je zdravilo Vibativ v času nosečnosti kontraindicirano.
That there is a risk of infusion related reactions including red man syndrome-like reactions.
Obstaja tveganje za reakcije, povezane z infundiranjem, vključno z reakcijami, ki so podobne eritrodermiji.
That there is a risk of severe liver injury and so regular measurement of ALT (SGPT ) levels to monitor liver function is important.
Da obstaja tveganje za hudo jetrno poškodbo in zato je pomembno redno spremljanje jetrne funkcije z meritvami vrednosti ALT (SGPT).
That there is a risk of severe liver injury and so regular measurement of ALT (SGPT) levels to monitor liver function is important.
Da obstaja tveganje za hudo jetrno poškodbo in zato je pomembno redno spremljanje jetrne funkcije z meritvami vrednosti ALT (SGPT).
That there is a risk of teratogenicity and so pregnancy must be avoided until leflunomide plasma levels are at an appropriate level.
Da obstaja tveganje za teratogenost, zato se je potrebno izogniti nosečnosti dokler niso dosežene primerne plazemske vrednosti leflunomida.
That there is a risk of teratogenicity and so pregnancy must be avoided until leflunomide plasma levels are at an appropriatelevel.
Da obstaja tveganje za teratogenost, zato se je potrebno izogniti nosečnosti dokler niso dosežene primerne plazemske vrednosti leflunomida.
That there is an identified risk of ototoxicity and patients developing ototoxicity signs or symptoms or patients receiving other medicinal products with ototoxic potential should be carefully evaluated and monitored.
Obstaja ugotovljeno tveganje za ototoksičnost ter da je treba bolnike, pri katerih se razvijejo znaki ali simptomi ototoksičnosti, oz. bolnike, ki prejemajo druga zdravila z ototoksičnim potencialom, skrbno oceniti in spremljati.
That there is an increased risk of renal disease in HIV infected patients associated with tenofovir disoproxil fumarate-containing products such as Atripla
Da pri bolnikih, okuženih z virusom HIV, obstaja povečano tveganje za ledvično bolezen, ki je povezano z zdravili, ki vsebujejo dizoproksiltenofovirijev fumarat, kot je zdravilo Atripla
That there is an interaction with hormonal contraceptives
da obstaja medsebojnodelovanje s hormonskimi kontracepctivi
That they are receiving Ruconest for treatment of acute attack of hereditary angioedema
da prejemajo zdravilo Ruconest za zdravljenje akutnih napadov dednega angioedema;
That they should be asked to carry the card and always show it to any health care professional treating them for acute attacks of hereditary angioedema.
opozorilo, naj imajo opozorilno kartico pri sebi in jo vedno pokažejo vsakemu zdravstvenemu delavcu, ki jih zdravi zaradi akutnih napadov dednega angioedema.
That they should consult their healthcare provider for further information;
Da se morajo za dodatne informacije posvetovati z zdravnikom.
That they will have a baseline ECG and blood pressure measurement prior to the first dose of GILENYA.
Bolniku bo treba posneti EKG in izmeriti krvni tlak pred prvim odmerjanjem zdravila GILENYA.
That treatment for hypersensitivity reactions, including measures for resuscitation should be available during administration
da mora biti med uporabo zdravila na voljo zdravljenje preobčutljivostnih reakcij, vključno z ukrepi za reanimacijo